CAESAREA, Israel, Nov. 8, 2023
/PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM)
("IceCure", "IceCure Medical" or the "Company"), developer of the
ProSense® System, a minimally-invasive cryoablation technology that
destroys tumors by freezing as an alternative to surgical tumor
removal, today announced that it will issue a press release with
its financial and operational results as of and for the nine months
ended September 30, 2023 before the
Nasdaq Stock Market opens on Wednesday,
November 15, 2023 and also discuss such results and other
corporate developments on a conference call at 10:00 a.m. EST on the same day.
Conference call & webcast info:
Wednesday, November 15, 2023,
at 10:00 am ET
US: 1-888-642-5032
Israel/International:
+972-3-9180609
A live webcast will be available at:
veidan.activetrail.biz/IcecureQ3-2023
A recording of the webcast will be available
at: ir.icecure-medical.com/
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®,
an advanced liquid-nitrogen-based cryoablation therapy for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The system is marketed and sold
worldwide for the indications cleared and approved to date
including in the U.S., Europe, and
China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal and
Israeli securities laws. Words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates" and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statement in this press release when it discusses that it
will issue a press release with its financial and operational
results as of and for the nine months ended September 30, 2023 on November 15, 2023 and discuss such results on a
conference call at 10:00 a.m EST that day. Because such statements
deal with future events and are based on IceCure's current
expectations, they are subject to various risks and uncertainties
and actual results, performance, or achievements of IceCure could
differ materially from those described in or implied by the
statements in this press release. Important factors that could
cause actual results, developments and business decisions to differ
materially from those anticipated in these forward-looking
statements include, among others: our planned level of
revenues and capital expenditures; our available cash and our
ability to obtain additional funding; our ability to market and
sell our products; legal and regulatory developments in
the United States and other
countries; our ability to maintain our relationships with
suppliers, distributors and other partners; our ability to maintain
or protect the validity of our patents and other intellectual
property; our ability to expose and educate medical professionals
about our products; political, economic and military instability in
the Middle East, specifically in
Israel; as well as those factors
set forth in the Risk Factors section of the Company's Annual
Report on Form 20-F for the year ended December 31, 2022 filed with the SEC on
March 29, 2023, and other documents
filed with or furnished to the SEC which are available on the
SEC's website, www.sec.gov. The Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/1941429/IceCure_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/icecure-medical-to-report-third-quarter-2023-financial--operational-results-on-november-15-2023-301981387.html
SOURCE IceCure Medical